Attrition factors in clinical trials of comorbid bipolar and substance-related disorders

Nicole Nomamiukor, E. Sherwood Brown

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: This study analyzed and defined specific factors that account for attrition in clinical research for patients with bipolar and substance-related disorders. Methods: Data were analyzed from two completed studies: an open-label trial of lamotrigine in patients with bipolar disorder (BPD) and cocaine-related disorder, and a placebo-controlled trial of quetiapine in patients with BPD and alcohol-related disorders. Correlations and Independent sample t-tests were performed to assess the impact of baseline characteristics including on length of study participation. Significance was set at the p = 0.05 level. Results: In the lamotrigine-treated patients, the presence of an amphetamine-related disorder, in addition to cocaine-related disorders, was associated with a shorter time in the study. In the quetiapine-treated patients higher scores on the Addiction Severity Index Legal subscale were associated with shorter length in the study. The presence of panic disorder was associated with shorter time in both studies. Limitations: Although the data were taken from the two largest clinical trials, to date, in patients with BPD and substance-related disorders, the sample sizes were relatively modest. In addition, the baseline assessments were somewhat different in the two studies limiting our ability to make conclusions on differences between patients with BPD and cocaine use versus alcohol use. Conclusions: This study adds to an emerging literature on the significance of panic disorder in patients with BPD.

Original languageEnglish (US)
Pages (from-to)284-288
Number of pages5
JournalJournal of Affective Disorders
Volume112
Issue number1-3
DOIs
StatePublished - Jan 2009

Fingerprint

Substance-Related Disorders
Clinical Trials
Bipolar Disorder
Cocaine-Related Disorders
Panic Disorder
Alcohol-Related Disorders
Amphetamine-Related Disorders
Aptitude
Bipolar and Related Disorders
Cocaine
Sample Size
Placebos
Alcohols
Research

Keywords

  • Alcohol
  • Attrition
  • BPD
  • Cocaine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Attrition factors in clinical trials of comorbid bipolar and substance-related disorders. / Nomamiukor, Nicole; Brown, E. Sherwood.

In: Journal of Affective Disorders, Vol. 112, No. 1-3, 01.2009, p. 284-288.

Research output: Contribution to journalArticle

@article{79c6d2a760d643b6b7a254c01f39f2fa,
title = "Attrition factors in clinical trials of comorbid bipolar and substance-related disorders",
abstract = "Background: This study analyzed and defined specific factors that account for attrition in clinical research for patients with bipolar and substance-related disorders. Methods: Data were analyzed from two completed studies: an open-label trial of lamotrigine in patients with bipolar disorder (BPD) and cocaine-related disorder, and a placebo-controlled trial of quetiapine in patients with BPD and alcohol-related disorders. Correlations and Independent sample t-tests were performed to assess the impact of baseline characteristics including on length of study participation. Significance was set at the p = 0.05 level. Results: In the lamotrigine-treated patients, the presence of an amphetamine-related disorder, in addition to cocaine-related disorders, was associated with a shorter time in the study. In the quetiapine-treated patients higher scores on the Addiction Severity Index Legal subscale were associated with shorter length in the study. The presence of panic disorder was associated with shorter time in both studies. Limitations: Although the data were taken from the two largest clinical trials, to date, in patients with BPD and substance-related disorders, the sample sizes were relatively modest. In addition, the baseline assessments were somewhat different in the two studies limiting our ability to make conclusions on differences between patients with BPD and cocaine use versus alcohol use. Conclusions: This study adds to an emerging literature on the significance of panic disorder in patients with BPD.",
keywords = "Alcohol, Attrition, BPD, Cocaine",
author = "Nicole Nomamiukor and Brown, {E. Sherwood}",
year = "2009",
month = "1",
doi = "10.1016/j.jad.2008.04.016",
language = "English (US)",
volume = "112",
pages = "284--288",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Attrition factors in clinical trials of comorbid bipolar and substance-related disorders

AU - Nomamiukor, Nicole

AU - Brown, E. Sherwood

PY - 2009/1

Y1 - 2009/1

N2 - Background: This study analyzed and defined specific factors that account for attrition in clinical research for patients with bipolar and substance-related disorders. Methods: Data were analyzed from two completed studies: an open-label trial of lamotrigine in patients with bipolar disorder (BPD) and cocaine-related disorder, and a placebo-controlled trial of quetiapine in patients with BPD and alcohol-related disorders. Correlations and Independent sample t-tests were performed to assess the impact of baseline characteristics including on length of study participation. Significance was set at the p = 0.05 level. Results: In the lamotrigine-treated patients, the presence of an amphetamine-related disorder, in addition to cocaine-related disorders, was associated with a shorter time in the study. In the quetiapine-treated patients higher scores on the Addiction Severity Index Legal subscale were associated with shorter length in the study. The presence of panic disorder was associated with shorter time in both studies. Limitations: Although the data were taken from the two largest clinical trials, to date, in patients with BPD and substance-related disorders, the sample sizes were relatively modest. In addition, the baseline assessments were somewhat different in the two studies limiting our ability to make conclusions on differences between patients with BPD and cocaine use versus alcohol use. Conclusions: This study adds to an emerging literature on the significance of panic disorder in patients with BPD.

AB - Background: This study analyzed and defined specific factors that account for attrition in clinical research for patients with bipolar and substance-related disorders. Methods: Data were analyzed from two completed studies: an open-label trial of lamotrigine in patients with bipolar disorder (BPD) and cocaine-related disorder, and a placebo-controlled trial of quetiapine in patients with BPD and alcohol-related disorders. Correlations and Independent sample t-tests were performed to assess the impact of baseline characteristics including on length of study participation. Significance was set at the p = 0.05 level. Results: In the lamotrigine-treated patients, the presence of an amphetamine-related disorder, in addition to cocaine-related disorders, was associated with a shorter time in the study. In the quetiapine-treated patients higher scores on the Addiction Severity Index Legal subscale were associated with shorter length in the study. The presence of panic disorder was associated with shorter time in both studies. Limitations: Although the data were taken from the two largest clinical trials, to date, in patients with BPD and substance-related disorders, the sample sizes were relatively modest. In addition, the baseline assessments were somewhat different in the two studies limiting our ability to make conclusions on differences between patients with BPD and cocaine use versus alcohol use. Conclusions: This study adds to an emerging literature on the significance of panic disorder in patients with BPD.

KW - Alcohol

KW - Attrition

KW - BPD

KW - Cocaine

UR - http://www.scopus.com/inward/record.url?scp=56249103097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249103097&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2008.04.016

DO - 10.1016/j.jad.2008.04.016

M3 - Article

C2 - 18511129

AN - SCOPUS:56249103097

VL - 112

SP - 284

EP - 288

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-3

ER -